These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
449 related articles for article (PubMed ID: 17855633)
1. A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification. Mueller D; Bach C; Zeisig D; Garcia-Cuellar MP; Monroe S; Sreekumar A; Zhou R; Nesvizhskii A; Chinnaiyan A; Hess JL; Slany RK Blood; 2007 Dec; 110(13):4445-54. PubMed ID: 17855633 [TBL] [Abstract][Full Text] [Related]
2. The mixed-lineage leukemia fusion partner AF4 stimulates RNA polymerase II transcriptional elongation and mediates coordinated chromatin remodeling. Bitoun E; Oliver PL; Davies KE Hum Mol Genet; 2007 Jan; 16(1):92-106. PubMed ID: 17135274 [TBL] [Abstract][Full Text] [Related]
3. MLL-AF9 and MLL-ENL alter the dynamic association of transcriptional regulators with genes critical for leukemia. Monroe SC; Jo SY; Sanders DS; Basrur V; Elenitoba-Johnson KS; Slany RK; Hess JL Exp Hematol; 2011 Jan; 39(1):77-86.e1-5. PubMed ID: 20854876 [TBL] [Abstract][Full Text] [Related]
7. Function of leukemogenic mixed lineage leukemia 1 (MLL) fusion proteins through distinct partner protein complexes. Biswas D; Milne TA; Basrur V; Kim J; Elenitoba-Johnson KS; Allis CD; Roeder RG Proc Natl Acad Sci U S A; 2011 Sep; 108(38):15751-6. PubMed ID: 21896721 [TBL] [Abstract][Full Text] [Related]
8. A higher-order complex containing AF4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-dependent transcription. Yokoyama A; Lin M; Naresh A; Kitabayashi I; Cleary ML Cancer Cell; 2010 Feb; 17(2):198-212. PubMed ID: 20153263 [TBL] [Abstract][Full Text] [Related]
10. Targeting recruitment of disruptor of telomeric silencing 1-like (DOT1L): characterizing the interactions between DOT1L and mixed lineage leukemia (MLL) fusion proteins. Shen C; Jo SY; Liao C; Hess JL; Nikolovska-Coleska Z J Biol Chem; 2013 Oct; 288(42):30585-30596. PubMed ID: 23996074 [TBL] [Abstract][Full Text] [Related]
11. The leukemogenic AF4-MLL fusion protein causes P-TEFb kinase activation and altered epigenetic signatures. Benedikt A; Baltruschat S; Scholz B; Bursen A; Arrey TN; Meyer B; Varagnolo L; Müller AM; Karas M; Dingermann T; Marschalek R Leukemia; 2011 Jan; 25(1):135-44. PubMed ID: 21030982 [TBL] [Abstract][Full Text] [Related]
12. The Intrinsically Disordered Proteins MLLT3 (AF9) and MLLT1 (ENL) - Multimodal Transcriptional Switches With Roles in Normal Hematopoiesis, MLL Fusion Leukemia, and Kidney Cancer. Kabra A; Bushweller J J Mol Biol; 2022 Jan; 434(1):167117. PubMed ID: 34174329 [TBL] [Abstract][Full Text] [Related]
13. Small-molecule inhibitor of AF9/ENL-DOT1L/AF4/AFF4 interactions suppresses malignant gene expression and tumor growth. Wu F; Nie S; Yao Y; Huo T; Li X; Wu X; Zhao J; Lin YL; Zhang Y; Mo Q; Song Y Theranostics; 2021; 11(17):8172-8184. PubMed ID: 34373735 [TBL] [Abstract][Full Text] [Related]
14. Human Polymerase-Associated Factor complex (PAFc) connects the Super Elongation Complex (SEC) to RNA polymerase II on chromatin. He N; Chan CK; Sobhian B; Chou S; Xue Y; Liu M; Alber T; Benkirane M; Zhou Q Proc Natl Acad Sci U S A; 2011 Sep; 108(36):E636-45. PubMed ID: 21873227 [TBL] [Abstract][Full Text] [Related]
15. ENL, the MLL fusion partner in t(11;19), binds to the c-Abl interactor protein 1 (ABI1) that is fused to MLL in t(10;11)+. García-Cuéllar MP; Schreiner SA; Birke M; Hamacher M; Fey GH; Slany RK Oncogene; 2000 Mar; 19(14):1744-51. PubMed ID: 10777208 [TBL] [Abstract][Full Text] [Related]
16. MLL repression domain interacts with histone deacetylases, the polycomb group proteins HPC2 and BMI-1, and the corepressor C-terminal-binding protein. Xia ZB; Anderson M; Diaz MO; Zeleznik-Le NJ Proc Natl Acad Sci U S A; 2003 Jul; 100(14):8342-7. PubMed ID: 12829790 [TBL] [Abstract][Full Text] [Related]
18. The polycomb protein MPc3 interacts with AF9, an MLL fusion partner in t(9;11)(p22;q23) acute leukemias. Hemenway CS; de Erkenez AC; Gould GC Oncogene; 2001 Jun; 20(29):3798-805. PubMed ID: 11439343 [TBL] [Abstract][Full Text] [Related]
19. A carboxy-terminal domain of ELL is required and sufficient for immortalization of myeloid progenitors by MLL-ELL. DiMartino JF; Miller T; Ayton PM; Landewe T; Hess JL; Cleary ML; Shilatifard A Blood; 2000 Dec; 96(12):3887-93. PubMed ID: 11090074 [TBL] [Abstract][Full Text] [Related]
20. The elongation domain of ELL is dispensable but its ELL-associated factor 1 interaction domain is essential for MLL-ELL-induced leukemogenesis. Luo RT; Lavau C; Du C; Simone F; Polak PE; Kawamata S; Thirman MJ Mol Cell Biol; 2001 Aug; 21(16):5678-87. PubMed ID: 11463848 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]